Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients

• Published in: Scientific Reports Vol. 5; no. 1; p. 15437
• Main Authors: Horita, Nobuyuki, Yamamoto, Masaki, Sato, Takashi, Tsukahara, Toshinori, Nagakura, Hideyuki, Tashiro, Ken, Shibata, Yuji, Watanabe, Hiroki, Nagai, Kenjiro, Inoue, Miyo, Nakashima, Kentaro, Ushio, Ryota, Shinkai, Masaharu, Kudo, Makoto, Kaneko, Takeshi
• Format: Journal Article
• Language: English
• Published: London Springer Science and Business Media LLC 21.10.2015; Nature Publishing Group UK; Nature Publishing Group
• Subjects: 692/308/409; Anemia; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chemotherapy; Data processing; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - pathology; Humanities and Social Sciences; Humans; Lung cancer; Lung carcinoma; Meta-analysis; multidisciplinary; Neoplasm Recurrence, Local; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - epidemiology; Neoplasm Recurrence, Local - pathology; Neutropenia; Response rates; Science; Side effects; Small Cell Lung Carcinoma; Small Cell Lung Carcinoma - drug therapy; Small Cell Lung Carcinoma - epidemiology; Small Cell Lung Carcinoma - pathology; Thrombocytopenia; Topotecan; Topotecan - adverse effects; Topotecan - therapeutic use

Topotecan is the most reliable chemotherapy regimen for relapsed small-cell lung carcinoma (SCLC). The efficacy and adverse effects of topotecan as reported by previous studies varied greatly. The inclusion criterion was a prospective study that was able to provide data for 6-month over-all survival...